Top

Published in:

01-07-2010 | Basic Science

Animal models of immune thrombocytopenia (ITP)

Author: John W. Semple

Published in: Annals of Hematology | Special Issue 1/2010

Abstract

With regards to research animal models related to immune thrombocytopenia (ITP), there is an extensive literature of over 300 publications published since 1959. It appears that many of these models either confirm what has been found in human ITP or, in some instances, are the first to describe a phenomenon related to ITP that is still of relevance today in human medicine. These models will undoubtedly play a significant role in the future research of human ITP particularly related to understanding of the pathogenesis of the disorder and the development of novel therapeutics. This review will highlight some of the major animal models utilized for ITP research and will present a somewhat historical aspect of the subject.

Stasi R, Evangelista ML, Stipa E et al (2008) Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 99:4–13PubMed

Cines DB, Blanchette VS (2002) Immune thrombocytopenic purpura. N Eng J Med 346:995–1008

Hou M, Stockelberg D, Kutti J, Wadenvik H (1995) Antibodies against GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 55:307–314PubMedCrossRef

Mehta YS, Pathare AV, Badakere SS, Ghosh K, Mohanty D (2000) Influence of auto-antibody specificities on the clinical course in patients with chronic and acute ITP. Platelets 11:94–98PubMed

Fabris F, Scandellari R, Ruzzon E et al (2004) Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 103:4562–4564PubMed

Zhou B, Zhao H, Yang RC, Han ZC (2005) Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol/Hematol 54:107–116

Michel M (2009) Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J Haematol 82(suppl 71):3–7

Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393PubMed

Semple JW, Freedman J (1995) Abnormal cellular immune mechanisms associated with autoimmune thrombocytopenia. Transfusion Med Rev 9:327–338

10.

Semple JW (1998) Immunobiology of T helper cells and antigen-presenting cells in autoimmune thrombocytopenic purpura (ITP). Acta Pædiatr Suppl 424:41–45PubMed

11.

Coopamah M, Garvey MB, Freedman J, Semple JW (2003) Cellular immune mechanisms in autoimmune thrombocytopenic purpura: an update. Transfusion Med Rev 17:69–80

12.

Cooper N, Bussel J (2006) The pathogenesis of immune thrombocytopaenic purpura. Brit J Haematol 133:364–374

13.

Sakakura M, Wada H, Tawara I et al (2007) Reduced Cd4+ Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res 120:187–193PubMed

14.

Ling Y, Cao X, Yu Z, Ruan C (2007) Circulating dendritic cells subsets and CD4 + Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 79:310–316PubMed

15.

Liu B, Zhao H, Poon MC et al (2007) Abnormality of CD4(+) CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 78:139–143PubMed

16.

Stasi R, Del Poeta G, Stipa E et al (2007) Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110:2924–2930PubMed

17.

Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T cell changes in patients with idiopathic thrombocytopenic purpura receiving B-cell depleting therapy with rituximab. Blood 112:1147–1150PubMed

18.

Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H (2008) Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 12:1078–1084

19.

Yu J, Heck S, Patel V et al (2008) Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood 112:1325–1328PubMed

20.

Zhang X-L, Peng J, Sun J-Z et al (2009) De novo induction of platelet-specific CD4_CD25_ regulatory T cells from CD4_CD25_ cells in patients with idiopathic thrombocytopenic purpura. Blood 113:2568–2577PubMed

21.

You S, Alyanakian M-A, Segovia B et al (2008) Immunoregulatory pathways controlling progression of autoimmunity in NOD mice. Ann NY Acad Sci 1150:300–310PubMed

22.

Du Y, Fu Y, Mohan C (2008) Experimental anti-GBM nephritis as an analytical tool for studying spontaneous lupus nephritis. Arch Immunol Ther Exp 56(1):31–40

23.

Mix E, Meyer-Rienecker H, Zettl UK (2008) Animal models of multiple sclerosis for the development and validation of novel therapies—potential and limitations. J Neurol 255(Suppl 6):7–14PubMed

24.

Hurvitz WRJ, Dodds-Laffin WJ AI (1973) Immunologically mediated thrombocytopenia in the dog. J Amer Vet Med Assoc 163(3):277–282

25.

Putsche JC, Kohn B (2008) Primary immune-mediated thrombocytopenia in 30 dogs (1997–2003). J Amer Animal Hospital Assoc 44(5):250–257

26.

Hammill D, Helton M (1981) Idiopathic thrombocytopenia in a mare. Mod Vet Pract 62(5):392PubMed

27.

Jain NC, Switzer JW (1981) Autoimmune thrombocytopenia in dogs and cats. Vet Clin North Am, Small Anim Pract 11(2):421–434

28.

Williams DA, Maggio-Price L (1984) Canine idiopathic thrombocytopenia: clinical observations and long-term follow-up in 54 cases. J Am Vet Med Assoc 185(6):660–663PubMed

29.

Endicott M (2003) Oncologic emergencies. Clin Tech Small Anim Pract 18(2):127–130PubMed

30.

Rosti P, Zangaglia O (1955) Research on experimental thrombopenia III. Evaluation of the anti-platelet activity of an immune serum by means of agglutination of sensitized sheep erythrocytes with platelet antigen according to a modified Middlebrook–Dubos technic. Boll Ist Sieroter Milan 34:91–96PubMed

31.

Rossolini A, Pieri I, Malandrini F (1960) On the action of cortisone in thrombopenia induced in the guinea pig with heterologous immune serum. Riv Clin Pediatr 65:238–244PubMed

32.

Chieffi O, Benedetti PA, Lecchini L, Rossolini A (1964) Action of cortisone on neonatal thrombopenia provoked in the guinea pig with heterologous immune serum. Atti Accad Fisiocrit Siena Med Fis 13(1):463–470PubMed

33.

Pieri J, Malandrini F, Puglisi P, Rossolini A (1966) On neonatal thrombopenia in the guinea pig (possible passage of antibodies through the milk. Atti Accad Fisiocrit Siena [Med Fis] 15:293–300

34.

Kalmaz GD, McDonald TP (1981) Effects of antiplatelet serum and thrombopoietin on the percentage of small acetylcholinesterase-positive cells in bone marrow of mice. Exp Hematol 9:1002–1010PubMed

35.

McDonald TP, Kalmaz GD (1983) Effects of thrombopoietin on the number and diameter of marrow megakaryocytes of mice. Exp Hematol 11:91–97PubMed

36.

Bourebia DE, Najean J, Rosset AM Y (1983) Partial purification of a thrombocytopoiesis stimulating factor present in the serum of thrombocytopenic rats. Acta Haematol 69:249–253PubMed

37.

Rolovic Z, Baldini M, Dameshek W (1970) Megakaryocytopoiesis in experimentally induced immune thrombocytopenia. Blood 35:173–188PubMed

38.

Nakeff A, Roozendaal KJ (1975) Thrombopoietin activity in mice following immune-induced thrombocytopenia. Acta Haematol 54:340–344PubMed

39.

Marosi Z, Krizsa F, Rak K (1976) Thrombocytopoietic serum activity in thrombocytopenia induced by antithrombocytic serum in mice. Haematologia 10:249–253PubMed

40.

Odell TT, Murphy JR, Jackson CW (1976) Stimulation of megakaryocytopoiesis by acute thrombocytopenia in rats. Blood 48:765–775PubMed

41.

Joshi BC, Jain NC (1977) Experimental immunologic thrombocytopenia in dogs: a study of thrombocytopenia and megakaryocytopoiesis. Res Vet Sci 22:11–17PubMed

42.

McDonald TP (1978) A comparison of platelet production in mice made thrombocytopenic by hypoxia and by platelet specific antisera. Brit J Haematol 40:299–309

43.

Levin J, Levin FC, Metcalf D (1980) The effects of acute thrombocytopenia on megakaryocyte-CFC and granulocyte-macrophage-CFC in mice: studies of bone marrow and spleen. Blood 56:274–283PubMed

44.

Levin J, Levin FC, Penington DG et al (1981) Measurement of ploidy distribution in megakaryocyte colonies obtained from culture: with studies of the effects of thrombocytopenia. Blood 57:287–297PubMed

45.

Ebbe S, Levin J, Miller K et al (1987) Thrombocytopoietic response to immunothrombocytopenia in nude mice. Blood 69:192–198PubMed

46.

Stenberg PE, Levin J (1989) Ultrastructural analysis of acute immune thrombocytopenia in mice: dissociation between alterations in megakaryocytes and platelets. J Cell Physiol 141:160–169PubMed

47.

Krizsa F, Vezendi K, Borbenyi Z, Varga G, Cserhati I (1982) Effect of sera obtained from thrombocytopenic mice on syngeneic long-term bone marrow cultures. Exp Hematol 10:881–885PubMed

48.

Linklater KA (1977) Post-transfusion purpura in a pig. Res Vet Sci 22:257–258PubMed

49.

Moore S, Friedman RJ, Singal DP et al (1976) Inhibition of injury induced thromboatherosclerotic lesions by anti-platelet serum in rabbits. Thromb Haemost 35:70–81PubMed

50.

Wakisaka G, Yasuna GA, Kuramoto K et al (1964) An experimental study of immune thrombocytopenia induced by quinidine. Arerugi 13:686–689PubMed

51.

Ashida SI, Abiko Y (1975) Protective effect of pantethine on experimental thrombocytopenia in the rat. Thromb Diath Haemorrhagica 33:528–539

52.

Kekomaki R, Kauppinen HL, Penttinen K, Myllyla G (1977) Interactions of immune complexes and platelets in rabbits immunized with hapten-carrier conjugates. Acta Pathol Microbiol Scand, Sect C Immunol 85:207–214

53.

Ferguson PW, Anderson JH, Krieger RI (1979) Secondary thrombocytopenia following phenobarbital treatments in a rhesus monkey (Macaca mulatta). Lab Animal Sci 29:94–96

54.

Bloom JC, Blackmer SA, Bugelski PJ et al (1985) Gold-induced immune thrombocytopenia in the dog. Vet Pathol 22:492–499PubMed

55.

Reilly MP, Taylor SM, Hartman NK et al (2001) Fc{gamma}RIIA requires human platelet factor 4 and platelet activation through heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model. Blood 98:2442–2447PubMed

56.

Reilly MP, McKenzie SE (2002) Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. Curr Opin Hematol 9:395–400PubMed

57.

Lavergne SN, Trepanier LA (2007) Anti-platelet antibodies in a natural animal model of sulphonamide-associated thrombocytopaenia. Platelets 18:595–604PubMed

58.

Giles AR, Hoogedoorn H, Blajchman MA, Hirsh J (1980) The thrombogenicity of prothrombin complex concentrates: II. the effect of thrombocytopenia on in vivo thrombogenicity in rabbits. Thromb Res 17:555–560PubMed

59.

Barnhart DD, Gengozian N (1975) Actively induced thrombocytopenia in the marmoset. A possible autoimmune model. Clin Exp Immunol 21:493–500PubMed

60.

McDonald TP, Clift R (1976) Mechanism of thrombocytopenia induced in mice by anti-platelet serum. Haemost 5:38–50

61.

Dodds WJ (1977) Animal model: canine and equine immune-mediated thrombocytopenia, and idiopathic thrombocytopenic purpura. Amer J Pathol 86:489–491

62.

Gengozian N, McLaughlin CL (1978) Actively induced platelet-bound IgG associated with thrombocytopenia in the marmoset. Blood 51:1197–1210PubMed

63.

Krakowka S, Axthelm MK, Gorham JR (1987) Effects of induced thrombocytopenia on viral invasion of the central nervous system in canine distemper virus infection. J Comp Pathol 97:441–450PubMed

64.

Arnott J, Horsewood P, Kelton JG (1987) Measurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia. Blood 69:1294–1299PubMed

65.

Mylvaganam R, Sprinz PG, Ahn YS, Harrington WJ (1984) An animal model of alloimmune thrombocytopenia. I. The role of the mononuclear phagocytic system (MPS). Clin Immunol Immunopathol 31:163–170PubMed

66.

Dominguez V, Govezensky T, Gevorkian G, Larralde C (2003) Low platelet counts alone do not cause bleeding in an experimental immune thrombocytopenic purpura in mice. Haematologica 88:679–687PubMed

67.

Wei H, Ding X, Ren J et al (2008) A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen. J Genet Genom 35:665–671

68.

Newman PJ, Kahn RA, Hines A (1981) Detection and characterization of monoclonal antibodies to platelet membrane proteins. J Cell Biol 90:249–253PubMed

69.

McMichael AJ, Rust NA, Pilch JR et al (1981) Monoclonal antibody to human platelet glycoprotein I. I. Immunological studies. Brit J Haematol 49:501–509

70.

Ruan C, Tobelem G, McMichael AJ et al (1981) Monoclonal antibody to human platelet glycoprotein I. II. Effects on human platelet function. Brit J Haematol 49:511–519

71.

Vainchenker W, Deschamps JF, Bastin JM et al (1982) Two monoclonal antiplatelet antibodies as markers of human megakaryocyte maturation: immunofluorescent staining and platelet peroxidase detection in megakaryocyte colonies and in in vivo cells from normal and leukemic patients. Blood 59:514–521PubMed

72.

Di Minno G, Thiagarajan P, Perussia B et al (1983) Exposure of platelet fibrinogen-binding sites by collagen, arachidonic acid, and ADP: inhibition by a monoclonal antibody to the glycoprotein IIb-IIIa complex. Blood 61:140–148PubMed

73.

Tetteroo PA, Lansdorp PM, Leeksma OC, von dem Borne AE (1983) Monoclonal antibodies against human platelet glycoprotein IIIa. Brit J Haematol 55:509–522

74.

Colle BS (1984) Report of the working party on hybridoma-derived monoclonal antibodies to platelets. Thromb Haemost 51:169–173

75.

Ciaglowski RE, Martinez J, Ryan TJ et al (1986) Monoclonal antibodies to bovine platelet factor 4: species interactions to platelets and megakaryocytes using indirect immunocytofluorescence. Thromb Res 41:855–865PubMed

76.

Prendergast MM, Bradstock KF, Broomhead AF et al (1986) Monoclonal antibody analysis of canine hemopoietic cells. Role of Ia-like and Thy-1 antigens in bone marrow engraftment. Transplantation 41:565–571PubMed

77.

Rodriguez-Calvillo M, Gabari I, Duarte M et al (2001) Thrombopenic purpura induced by a monoclonal antibody directed to a 35-kilodalton surface protein (p35) expressed on murine platelets and endothelial cells. Exp Hemato 29:589–595

78.

Burstein SA, Friese P, Downs T, Mei RL (1992) Characteristics of a novel rat anti-mouse platelet monoclonal antibody: application to studies of megakaryocytes. Exp Hematol 20:1170PubMed

79.

Nieswandt B, Echtenacher B, Wachs F-P et al (1999) Acute systemic eaction and lung alterations induced by an antiplatelet integrin gpIIb/IIIa antibody in mice. Blood 94:684–691PubMed

80.

Nieswandt B, Bergmeier W, Rackebrandt K et al (2000) Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood 96:2520–2527PubMed

81.

Crow AR, Song S, Semple JW et al (2001) IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of anti-idiotype reactivity. Brit J Haematol 115:679–686

82.

Teeling JL, Jansen-Hendriks T, Kuijpers TE et al (2001) Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 98:1095–1099PubMed

83.

Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIg mediated through the inhibitory Fc receptor. Science 291:484–486PubMed

84.

Song S, Crow AR, Freedman J et al (2003) Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG. Blood 101:3708–3713PubMed

85.

Song S, Crow AR, Siragam V et al (2005) Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 105:1546–1548PubMed

86.

Siragam V, Crow AR, Brinc D et al (2006) Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12:688–692PubMed

87.

Leytin V, Sergiy M, Starkey AF et al (2006) Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 133:452–460, Erratum

88.

Crow AR, Song S, Semple JW et al (2007) A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg? Blood 09:155–158

89.

Tsubakio T, Hamano T, Shintome M et al (1987) Mechanism of increase in platelet count by intravenous gammaglobulin in thrombocytopenic rats. Acta Haematologica Jap 50:1031–1037

90.

Hansen RJ, Balthasar JP (2003) Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia. J Pharmaceut Sci 92:1206–1215

91.

Siragam V, Brinc D, Crow AR et al (2005) Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 115:155–160PubMed

92.

Park-Min KH, Serbina NV, Yang W et al (2007) FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26:67–78PubMed

93.

Deng R, Balthasar JP (2007) Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. J Pharmaceut Sci 96:25–37

94.

Crow AR, Lazarus AH (2008) The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfusion Med Rev 22:103–116

95.

Anthony RM, Nimmerjahn F, Ashline DJ et al (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320:373–376PubMed

96.

Kaveri SV, Lacroix-Desmazes S, Bayry J (2008) The antiinflammatory IgG. New Engl J Med 359:307–309PubMed

97.

Hang LM, Izui S, Dixon FJ (1981) A model of acute lupus and coronary vascular disease with myocardial infraction. J Exp Med 154:216–221PubMed

98.

Oyaizu N, Yasumizu R, Miyama-Inaba M et al (1988) A new animal of idiopathic thrombocytopenic purpura. J Exp Med 167:2017–2022PubMed

99.

Mizutani H, Furubayashi T, Kurlu A et al (1990) Analyses of thrombocytopenia in idiopathic thrombocytopenic purpura-prone mice by platelet transfer experiments between (NZW X BXSB) F₁ and normal mice. Blood 75:1809–1812PubMed

100.

Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA (1993) Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW x BXSB)F₁ mice. Blood 82:837–844PubMed

101.

Vanhoorelbeke MK, Deckmyn H, Coutelier J-P (2004) A new model of transient strain-dependent autoimmune thrombocytopenia in mice immunized with rat platelets. Exp Hematol 32:87–94PubMed

102.

Musaji A, Cormont F, Thirion G, Cambiaso CL, Coutelier JP (2004) Exacerbation of autoantibody mediated thrombocytopenia purpura by infection with mouse viruses. Blood 104:2102–2106PubMed

103.

Musaji A, Meite M, Detalle L et al (2005) Enhancement of autoantibody pathogenicity by viral infections in mouse models of anemia and thrombocytopenia. Autoimmune Rev 4:247–252

104.

Alves-Rosa F, Stanganelli C, Cabrera J et al (2000) Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 96:2834–2840PubMed

105.

Tremblay T, Aubin E, Lemieux R, Bazin R (2007) Picogram doses of lipopolysaccharide exacerbate antibody mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice. Brit J Haematol 139:297–302

106.

Semple JW, Aslam R, Kim M, Speck ER, Freedman J (2007) Platelet-bound lipopolysaccharide enhances Fc receptor-mediated phagocytosis of IgG opsonized platelets. Blood 109:4803–4805PubMed

107.

Asahi A, Nishimoto T, Okazaki Y et al (2008) Helicobacter pylori eradication shifts monocyte Fcγ receptor balance toward inhibitory FcγRIIB in immune thrombocytopenic purpura patients. J Clin Invest 118:2939–2949PubMed

108.

Ni H, Chen P, Spring CM et al (2006) A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 107:2976–2983PubMed

109.

Webster ML, Sayeh E, Crow M et al (2006) Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIb antibodies. Blood 108:943–946PubMed

110.

Go RS, Johnston KL, Bruden KC (2007) The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 92(2):283–284PubMed

111.

Chow L, Kim M, Speck ER et al. (2009). A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood (in press)

Title: Animal models of immune thrombocytopenia (ITP)
Author: John W. Semple
Publication date: 01-07-2010
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue Special Issue 1/2010
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-009-0882-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Health-related quality of life outcomes for patients with immune thrombocytopenic purpura

Consensus Paper—ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia

ICIS supplementum abstracts

Genetic studies in pediatric ITP: outlook, feasibility, and requirements

Mechanisms of platelet recovery in ITP associated with therapy

The working group for “basic science” in ITP at the International Cooperative ITP Study Group (ICIS)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials